OCGN 8-K
Ocugen, Inc. (OCGN)
8-K
2021-08-06
For: 2021-08-06
View Original
Added on
April 08, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
___________________________________________________________
FORM 8-K
___________________________________________________________
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 6, 2021
___________________________________________________________
(Exact Name of Registrant as Specified in its Charter)
___________________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||||||||
(484 ) 328-4701
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
(The Nasdaq Capital Market) | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 6, 2021, Ocugen, Inc. ("the Company") issued a press release announcing its financial results for the quarter ended June 30, 2021. The Company has scheduled a conference call and webcast for 8:30 a.m. eastern time on August 6, 2021 to discuss these financial results and business updates. The Company will use presentation materials in connection with the conference call and webcast, which presentation materials will be posted on the Company's website at www.ocugen.com. Copies of the press release and presentation materials are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure
The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference. The information disclosed under Items 2.02 and 7.01, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events
Attached as Exhibit 99.3 and incorporated herein by reference is a presentation that the Company will post on its website on August 6, 2021 and may use from time to time in presentations or discussions with investors, analysts, and other parties.
Item 9.01 Financial Statements and Exhibits
The following exhibits are being filed or furnished (as applicable) herewith:
(d) Exhibits
| Exhibit No. | Document | |||||||
| 99.1 | ||||||||
| 99.2 | ||||||||
| 99.3 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 6, 2021
| OCUGEN, INC. | ||||||||
| By: | /s/ Shankar Musunuri | |||||||
| Name: Shankar Musunuri | ||||||||
| Title: Chief Executive Officer and Chairman | ||||||||
2
Exhibit 99.1
Ocugen Provides Business Update and Second Quarter 2021 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET
•Rolling regulatory submission to Health Canada completed and review process initiated; U.S. FDA talks continue
•Multiple milestones achieved across regulatory and supply chain to support potential commercialization of pipeline assets
•The Company experienced organizational growth to reflect new business requirements in clinical development, manufacturing, and commercialization
MALVERN, Pa. — August 6, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported second quarter 2021 financial results along with a general business update.
“The second quarter has proven how dynamic the life sciences sector is during this time of global crisis, and we are undeterred in our efforts to contribute to the public health agenda. Our regulatory submission to Health Canada and our ongoing discussions with the U.S. Food and Drug Administration continue to provide us direction in potentially obtaining regulatory approvals for COVAXIN™ in North America. We are also continuing our forward momentum to take on blindness diseases and are on track to initiate our first gene therapy clinical trial for OCU400 in the latter part of 2021. Overall, I’m very pleased with our growth and efforts to date,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
Business Highlights
FORWARD MOMENTUM FOR COVAXIN™ AND OPHTHALMIC PIPELINE
•The Company’s partner, Bharat Biotech of India, completed and posted its Phase 3 clinical trial results for COVAXIN™ demonstrating 77.8% efficacy against overall COVID-19 disease, 93.4% efficacy against severe COVID-19 disease, 63.6% efficacy against asymptomatic COVID-19 disease, and 65.2% efficacy against the Delta variant, B.1.617.2. Adverse events in the COVAXIN™ and control arms of the Phase 3 clinical trial were observed in 12.4% of subjects, with less than 0.5% of subjects experiencing serious adverse side effects. This data was submitted to a peer-reviewed journal for future potential publication.
•In June, an amendment to the agreement with Bharat Biotech was finalized which expanded the Company’s rights to develop, manufacture, and commercialize COVAXIN™ into Canada (in addition to the United States). Soon after in July, the Company announced the completion of its regulatory submission to Health Canada for COVAXIN™, which was accepted under the Minister of Health’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 and transitioned to a New Drug Submission for COVID-19. The submission was conducted through the Company’s new affiliate, Vaccigen, Ltd., and the review process has begun in Canada.
•Discussions with the U.S. Food and Drug Administration are ongoing, and the Company is still proceeding with a strategy focused on the agency’s requested Biologics License Application pathway and determining what data requirements and U.S.-based clinical trials will be required to support such submission.
•Technology transfer activities are ongoing between Bharat Biotech and Jubilant HollisterStier, which the Company has selected to be its contract manufacturing partner with respect to COVAXIN™.
•The Company’s development activities targeting retinal diseases based on its breakthrough modifier gene therapy platform continue to progress. Its first candidate therapy, OCU400, is anticipated to move into two parallel Phase 1/2a clinical trials in the United States later this year. The Company is currently also evaluating options to commence OCU400 clinical trials in Europe in 2022.
COMPANY POSITIONING FOR FUTURE GROWTH
•New management team member, Mike Shine, joined the Company in early June as Senior Vice President, Commercial, bringing nearly 35 years of industry experience. Mr. Shine will lead commercial efforts for the Company’s portfolio including COVAXIN™’s launch in Canada and the United States, if authorized or approved.
•Employee count has grown as the Company establishes enhanced capabilities in Research and Development, Clinical Development, Commercial, Supply Chain, and Communications.
•The Company entered the Russell 2000 and 3000 Indices in June, which reflects the organization’s performance, growth, and value.
Second Quarter 2021 Financial Results
•Ocugen’s cash, cash equivalents, and restricted cash totaled $115.8 million as of June 30, 2021, compared to $24.2 million as of December 31, 2020. Ocugen had 198.7 million shares of common stock outstanding as of June 30, 2021.
•Research and development expenses for the three months ended June 30, 2021 were $18.9 million compared to $1.6 million for the three months ended June 30, 2020. Research and development expenses for the three months ended June 30, 2021 included a $15.0 million up-front payment to Bharat Biotech for the right and license to COVAXIN™ development, manufacturing, and commercialization in Canada. General and administrative expenses for the three months ended June 30, 2021 were $6.8 million compared to $1.8 million for the three months ended June 30, 2020. Ocugen reported a $0.13 net loss per share for the three months ended June 30, 2021 compared to a $0.19 net loss per share for the three months ended June 30, 2020.
Conference Call and Webcast Details
Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights. Ocugen's senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.
The call can be accessed by dialing (844) 873-7330 (U.S.) or (602) 563-8473 (international) and providing the conference ID 6663619. To access a live audio webcast of the call on the “Investors” section of the Ocugen website, please click here. A replay of the webcast will be archived on Ocugen’s website for approximately 45 days following the call.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, including the risk that such dates are not met due to impacts from the ongoing COVID-19 pandemic, as well as risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether we will be able to provide the U.S. Food and Drug Administration (“FDA”) with sufficient additional information regarding the design of and results from preclinical and clinical studies of COVAXIN™, which have been conducted by Bharat Biotech in India in order for those trials to support a Biologics License Application (“BLA”); the size, scope, timing and outcome of any additional trials or studies that we may be required to conduct to support a BLA; any additional chemistry, manufacturing, and controls information that we may be required to submit; the timing of our BLA filing; whether and when a BLA for COVAXIN™ will be submitted to the FDA; whether and when a BLA may be approved by the FDA, an application for authorization under the Interim Order for emergency use may be approved by Health
Canada, or a New Drug Submission application may be approved by Health Canada, which authorizations or approvals will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if authorized or approved, whether it will be commercially successful; whether developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada, or other jurisdictions; manufacturing capabilities, manufacturing capacity, and supply restrictions, including whether sufficient doses of COVAXIN™ can be manufactured or supplied within our projected time periods; market demand for COVAXIN™ in the United States or Canada; decisions by the FDA or Health Canada impacting labeling, manufacturing processes, safety, and/or other matters that could affect the availability or commercial potential of COVAXIN™ in the United States or Canada, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
+1 484 237 3398
Please submit investor-related inquiries to: [email protected]
(tables to follow)
OCUGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
(Unaudited)
| June 30, 2021 | December 31, 2020 | ||||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 115,642 | $ | 24,039 | |||||||
| Advance for COVAXIN supply | 4,988 | — | |||||||||
| Prepaid expenses and other current assets | 996 | 1,839 | |||||||||
| Total current assets | 121,626 | 25,878 | |||||||||
| Property and equipment, net | 944 | 633 | |||||||||
| Restricted cash | 151 | 151 | |||||||||
| Other assets | 1,530 | 714 | |||||||||
| Total assets | $ | 124,251 | $ | 27,376 | |||||||
| Liabilities and stockholders’ equity | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable | $ | 802 | $ | 395 | |||||||
| Accrued expenses and other current liabilities | 3,870 | 2,941 | |||||||||
| Short-term debt, net | — | 234 | |||||||||
| Operating lease obligation | 168 | 44 | |||||||||
| Total current liabilities | 4,840 | 3,614 | |||||||||
| Non-current liabilities | |||||||||||
| Operating lease obligation, less current portion | 1,328 | 389 | |||||||||
| Long term debt, net | 1,674 | 1,823 | |||||||||
| Total liabilities | 7,842 | 5,826 | |||||||||
| Stockholders’ equity | |||||||||||
| Convertible preferred stock | 1 | — | |||||||||
| Common stock | 1,988 | 1,841 | |||||||||
| Treasury stock | (48) | (48) | |||||||||
| Additional paid-in capital | 220,799 | 93,059 | |||||||||
| Accumulated deficit | (106,331) | (73,302) | |||||||||
| Total stockholders’ equity | 116,409 | 21,550 | |||||||||
| Total liabilities and stockholders’ equity | $ | 124,251 | $ | 27,376 | |||||||
OCUGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Collaboration revenue | $ | — | $ | 43 | $ | — | $ | 43 | |||||||||||||||
| Total revenues | — | 43 | — | 43 | |||||||||||||||||||
| Operating expenses | |||||||||||||||||||||||
| Research and development | 18,853 | 1,630 | 21,725 | 3,282 | |||||||||||||||||||
| General and administrative | 6,757 | 1,779 | 10,942 | 4,056 | |||||||||||||||||||
| Total operating expenses | 25,610 | 3,409 | 32,667 | 7,338 | |||||||||||||||||||
| Loss from operations | (25,610) | (3,366) | (32,667) | (7,295) | |||||||||||||||||||
| Other income (expense) | |||||||||||||||||||||||
| Interest income | 10 | — | 10 | — | |||||||||||||||||||
| Interest expense | (20) | (248) | (40) | (263) | |||||||||||||||||||
| Other income (expense) | (332) | — | (332) | — | |||||||||||||||||||
| Total other income (expense) | (342) | (248) | (362) | (263) | |||||||||||||||||||
| Net loss | $ | (25,952) | $ | (3,614) | $ | (33,029) | $ | (7,558) | |||||||||||||||
| Deemed dividend related to Warrant Exchange | — | (12,546) | — | (12,546) | |||||||||||||||||||
| Net loss to common stockholders | $ | (25,952) | $ | (16,160) | $ | (33,029) | $ | (20,104) | |||||||||||||||
| Shares used in calculating net loss per common share — basic and diluted | 195,572,189 | 83,537,463 | 190,960,775 | 68,082,346 | |||||||||||||||||||
| Net loss per share of common stock — basic and diluted | $ | (0.13) | $ | (0.19) | $ | (0.17) | $ | (0.30) | |||||||||||||||
Q2 2021 Results August 6, 2021
Business update Financial performance Q2 2021 Results August 6, 2021
Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, including the risk that such dates are not met due to impacts from the ongoing COVID-19 pandemic, as well as risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether we will be able to provide the U.S. Food and Drug Administration (“FDA”) with sufficient additional information regarding the design of and results from preclinical and clinical studies of COVAXIN™, which have been conducted by Bharat Biotech in India in order for those trials to support a Biologics License Application (“BLA”); the size, scope, timing and outcome of any additional trials or studies that we may be required to conduct to support a BLA; any additional chemistry, manufacturing, and controls information that we may be required to submit; the timing of our BLA filing; whether and when a BLA for COVAXIN™ will be submitted to the FDA; whether and when a BLA may be approved by the FDA, an application for authorization under the Interim Order for emergency use may be approved by Health Canada, or a New Drug Submission application may be approved by Health Canada, which authorizations or approvals will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if authorized or approved, whether it will be commercially successful; whether developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada, or other jurisdictions; manufacturing capabilities, manufacturing capacity, and supply restrictions, including whether sufficient doses of COVAXIN™ can be manufactured or supplied within our projected time periods; market demand for COVAXIN™ in the United States or Canada; decisions by the FDA or Health Canada impacting labeling, manufacturing processes, safety, and/or other matters that could affect the availability or commercial potential of COVAXIN™ in the United States or Canada, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this presentation speak only as of the date of this presentation. Except as required by law, we assume no obligation to update forward-looking statements contained in presentation whether as a result of new information, future events, or otherwise, after the date of this presentation. 3
COVAXIN™: Forward momentum in dynamic environment Canada • Expanded rights to develop, commercialize and manufacture COVAXIN™ in Canada • Regulatory review process has begun following the completion of a rolling submission to Health Canada • Established Canadian affiliate – Vaccigen – to manage potential COVAXIN™ introduction United States • Discussions continue with the U.S. Food and Drug Administration around new clinical data required for submission of Biologics License Application Phase 3 clinical data Efficacy • Overall: 77.8% (95% CI: 65.2 – 86.4) • Against severe disease: 93.4% (95% CI: 57.1 – 99.8) • Against asymptomatic disease: 63.6% (95% CI: 29.0 – 82.4) • Against B.1.617.2 (Delta): 65.2% (95% CI: 33.1 – 83.0) Safety • Outcomes: 12.4% reported adverse events (AE) in both vaccine and placebo arms (p<0.05) Manufacturing infrastructure • Tech transfer ongoing with Jubilant HollisterStier • Supply chain team expanded 5
OCU400 – On track for late 2021 clinical trials A novel gene therapy product candidate with the potential to restore retinal integrity and function across a range of genetically-diverse, inherited retinal diseases Two Phase 1/2a clinical trials planned for Q4 2021 in the United States RHO NR2E3 Toxicology studies progressing with an upcoming readout ahead of clinical trial initiation 6
Financial update June 30, 2021 June 30, 2020 Research and development expense (18.9)$ (1.6)$ General and administrative expense (6.8) (1.8) Other income (expense), net (0.3) (0.2) Net loss (26.0)$ (3.6)$ Net loss to common stockholders (26.0)$ (16.2)$ Net loss per share of common stock — basic and diluted (0.13)$ (0.19)$ Balance Sheet Data June 30, 2021 December 31, 2020 Cash, cash equivalents, and restricted cash 115.8$ 24.2$ Debt 1.7$ 2.1$ Shares outstanding 198.7 184.0 (in millions, except per share amounts) Three months ended Statements of Operations 7
8 Q & A
9 Thank you
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID‐19 NASDAQ: OCGN Corporate Deck: August 2021
1©2021 Ocugen. All Rights Reserved. Forward Looking Statement This presentation contains forward‐looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, product approvals, research and development costs, timing and likelihood of success, estimated market size or growth, and plans and objectives of management for future operations, are forward‐looking statements. When used in this presentation, the words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward‐looking statements, although not all forward‐looking statements contain these identifying words. Forward‐looking statements involve known and unknown risks, uncertainties and other factors, including those risks set forth in the Company’s filings with the Securities and Exchange Commission, which are available at www.sec.gov, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‐looking statements. Forward‐looking statements are based on our management’s beliefs and assumptions and on information available to management as of the date of this presentation. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward‐looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward‐looking statements, even if new information becomes available in the future. This presentation includes estimates by us of statistical data relating to market size and growth and other estimated data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. This presentation also includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third‐party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third‐party research, surveys and studies are reliable, we have not independently verified such data. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
2©2021 Ocugen. All Rights Reserved. Ocugen Overview VACCINE • COVAXIN™: Whole‐virion inactivated COVID‐19 vaccine candidate (with adjuvant). Licensed rights from Bharat Biotech for the US and Canadian markets (currently received EUA in India). Standard vaccine storage condition (2‐8°C) • Demonstrated 77.8% overall efficacy, 93.4% in severe COVID‐19 disease (including hospitalization) and 65.2% efficacy against Delta variant in Phase 3 trial by Bharat Biotech • Phase 3 clinical trial enrolled 25,800 participants between 18‐98 years of age, including 2,760 over the age of 60 and 7,058 with at least one pre‐existing condition. Phase 1/2 enrolled 755 participants • Potential coverage against multiple protein antigens of the virus and potentially applicable to broader population, including 12– 17‐year‐olds (as seen in Phase 2 study) • Effectively neutralizes additional Kappa, Zeta, and Alpha variants of SARS‐Cov‐2 reducing the possibility of mutant virus escape • Rolling submission with Health Canada completed (July 2021) MODIFIER GENE THERAPY PLATFORM • Potential for one product to treat many diseases & multi‐factor approach (POC study results published in Nature) • OCU400 (AAV‐hNR2E3): Orphan medicinal product designation for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA) covering diseases caused by mutations in over 175 genes. Initiation of Phase 1/2a this year • OCU410 (AAV‐hRORA): Potential to treat dry age‐related macular degeneration (Dry AMD) through multi‐factor treatment approach – initiation of Phase 1/2 in 2022 • Strategic manufacturing partnership with CanSinoBio (~$13B market cap) – sets clear path for critical manufacturing NOVEL BIOLOGIC • OCU200: Targeting major retinal diseases: Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age‐Related Macular Degeneration (Wet AMD) (estimated global market size over $10B) – initiation of Phase 1/2 in 2022 • Novel MoA: Potential to initially treat non‐responders to anti‐VEGF/ therapies (~50% of patients)
3©2021 Ocugen. All Rights Reserved. Leadership Team Sanjay Subramanian, MBA CFO and Head of Corporate Development Vijay Tammara, PhD SVP, Regulatory & Quality Jessica Crespo, CPA Corporate Controller and Treasurer Arun Upadhyay, PhD VP, Head of Research & Development Shankar Musunuri, PhD, MBA Chairman, CEO and Co‐Founder Zara Gaudioso, SHRM‐CP Head of Human Resources J.P. Gabriel SVP, Manufacturing & Supply Chain Bruce D. Forrest, MB, BS, MD, MBA Acting CMO Michael Shine, MBA SVP, Commercial
4©2021 Ocugen. All Rights Reserved. Scientific Advisory Boards Satish Chandran, PhD David Fajgenbaum, MD, MBA, MSc, FCPP Bruce D. Forrest, MB, BS, MD, MBA Catherine Pachuk, PhD Harvey Rubin, MD, PhD Susan Weiss, PhD Carl D. Regillo, MD, FACS Mark Pennesi, MD, PhD Geeta Lalwani, MDDavid Boyer, MD Retina Scientific Advisory Board Vaccine Scientific Advisory Board
5©2021 Ocugen. All Rights Reserved. Pipeline and Regulatory overview VACCINE MODIFIER GENE THERAPY PLATFORM NOVEL BIOLOGIC Asset/Program Indication NotesPhase COVAXIN™ Whole‐Virion Inactivated Vaccine COVID‐19 Phase 3* Rolling submission with Health Canada completed (July 2021); Discussions with FDA ongoing OCU400 AAV‐hNR2E3 OCU410 AAV‐hRORA NR2E3 Mutation – Associated Retinal Degeneration** RHO Mutation – Associated Retinal Degeneration** CEP290 Mutation – Associated Retinal Degeneration** PDE6B Mutation – Associated Retinal Degeneration** Dry Age‐Related Macular Degeneration (Dry AMD) OCU200 Transferrin – Tumstatin Diabetic Macular Edema Diabetic Retinopathy Wet Age‐Related Macular Degeneration (Wet AMD) IND‐Enabling IND‐Enabling IND‐Enabling IND‐Enabling Preclinical Preclinical Preclinical Preclinical Orphan designation US & EU† ** No approved therapies exist https://www.aao.org/eye‐health/diseases/retinitis‐pigmentosa‐treatment https://www.aao.org/eye‐health/diseases/amd‐treatment † EU orphan medicinal product designation for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA) *Bharat Biotech‐sponsored clinical trial
6 COVAXIN™ Investigational Whole‐Virion Inactivated COVID‐19 Vaccine Licensed from Bharat Biotech (BBIL) for the US and Canadian Markets
7©2021 Ocugen. All Rights Reserved. COVAXIN™ ‐ Product Profile DOSE LEVEL and REGIMEN PRESENTATION STORAGE 0.5mL per dose suspension 2 Doses: Day 0 & Day 28 2°‐ 8°C (Expected shelf‐life ~2 Yrs.) Room temp (25ºC): 3 Months 10 doses per vial PROPOSED INDICATION TARGET POPULATION 12 years of age and older Active Immunization to Prevent COVID‐ 19 caused by SARS‐CoV‐2 Whole virion inactivated SARS‐CoV‐2 (NIV‐2020‐770) Antigen concentration & Adjuvant: 6μg + Algel–IMDG(TLR7/8)
8©2021 Ocugen. All Rights Reserved. B Both humoral & cellular responses generated against multiple viral proteins Induces a Th1 response (cell‐mediated immunity) Broad Spectrum Immune Response E Effective in neutralizing multiple variants, including rapidly‐spreading Delta variant (65.2% efficacy) Potentially serve as a universal booster to minimize/eliminate viral escape and control the Pandemic Efficacy 77.8% Efficacy Demonstrated in Phase 3 Trial (93.4% against severe) S Proven technology platform and supply chain currently used for several licensed vaccines (Influenza, Polio, Rabies, JEV etc.). Historically demonstrated acceptable safety, tolerability and efficacy consistent with adults Safe in 12+ (Demonstrated in Phase 2 clinical trial) T Stable for 3 months at room temperature Can be stored in standard conditions (2°‐ 8°C) for several years. Can be stockpiled. Transportation and Storage Ease Why COVAXIN™ Designed to fill a significant unmet need in our North American arsenal of vaccines against COVID‐19
9©2021 Ocugen. All Rights Reserved. Spike (S)Nucleocapsid (N) Membrane (M) Small membrane Protein (E) COVAXIN™ Presents Multiple Protein Targets to the Immune System Resulting in Broad Spectrum Response Spike (S) COVAXIN™ mRNA and Adenovirus‐Based Vaccines COVAXIN™, an adjuvanted inactivated virus vaccine candidate, elicited strong IgG responses against spike (S1) protein, receptor‐binding domain (RBD), and the nucleocapsid (N) protein of SARS‐CoV‐2 along with strong cellular responses
10©2021 Ocugen. All Rights Reserved. COVAXIN™ Developed and Manufactured by Bharat Biotech Established Robust Manufacturing Process for COVAXIN Ocugen licensed COVAXIN™ on the back of Bharat’s strong track record of developing & commercializing vaccines globally Inactivated Vero cell derived vaccines are proven, time‐tested and long‐ lasting. A few include:
11©2021 Ocugen. All Rights Reserved. COVAXIN™ is Distinct Amongst Leading COVID‐19 Vaccines and Select Vaccine Candidates in the United States and Canada Company Technology Antigen Status in US & Canada COVAXIN™ Inactivated SARS CoV‐2 Virus, Aluminum hydroxide, TLR agonist Whole virus (Including S & N Proteins) Rolling submission with Health Canada completed; BLA submission to be pursued in US Pfizer/ BioNTech Lipoplex of SARS CoV‐2 S protein mRNA S protein EUA in US; Authorized by Interim Order in Canada Moderna Lipoplex of SARS CoV‐2 S protein mRNA S protein EUA in US; Authorized by Interim Order in Canada AstraZeneca Non‐replicating infectious Adenovirus S protein Authorized by Interim Order in Canada Johnson & Johnson Non‐replicating infectious Adenovirus S protein EUA in US; Authorized by Interim Order in Canada
12©2021 Ocugen. All Rights Reserved. Technology Comparisons: Target Product Profile Characteristic mRNA Adeno‐ Based COVAXIN™ Acceptable Safety ✓ ✓ ✓ Neutralizing antibody response ✓ ✓ ✓+ Cellular responses against multiple viral antigens ✓ ✓ ✓+ Efficacy ✓ ✓ ✓+ Stability at 2‐8oC X ✓ ✓ Multiple Viral Antigens X X ✓ “+” : B and T cell immune responses to multiple proteins, Safety and Efficacy in Phase 3 clinical trial by Bharat Biotech
13©2021 Ocugen. All Rights Reserved. COVAXIN™ Progress and Planned Milestones for North American Development Ocugen signs Definitive Agreement for COVAXIN™ in US 1H 2021 2H 2021 EUA in India Start of mass immunization Phase 3 Interim Analysis Results Establish COVAXIN™ Manufacturing in US • Phase 3 data analysis completed • Rolling submission with Health Canada completed • BLA submission to be pursued in US; discussions ongoing to determine filing pathway • Initial US Supply from Partner, BBIL • Execute Tech Transfer to US Sites • Target 100M Doses/Year Click to access publication Phase 3 Full Results Rolling submission with Health Canada completed
14©2021 Ocugen. All Rights Reserved. FINAL Phase 3 Clinical Trial Results Demonstrate Protective Effect of COVAXIN™ Overall vaccine efficacy: 77.8% (95% CI: 65.2 – 86.4) Efficacy against severe disease: 93.4% (95% CI: 57.1 – 99.8) Efficacy against asymptomatic disease: 63.6% (95% CI: 29.0 – 82.4) Safety outcomes: 12.4% reported adverse events (AE) in vaccine or placebo arms (p<0.05) • Most frequently reported systemic AEs included headache, followed by pyrexia, fatigue and myalgia • Serious AEs were reported by <0.5% of clinical trial participants Demonstrated Efficacy against B.1.617.2 (Delta): 65.2% (95% CI: 33.1 – 83.0) • First Phase 3 clinical trial to include Delta variant data Fast facts of a double‐blind, randomized, multicenter, Phase 3 clinical trial • Subjects recruited between November 2020 and January 2021 across 25 sites • 1:1 randomization among healthy adults (age 18‐98 years) • n = 25,798 • Primary endpoint: Preventing symptomatic COVID‐19 occurring at least 14 days after second dose • Secondary endpoint: Efficacy in subgroups based on age (18 ‐ <60 years; ≥60 years) • Evaluated safety, reactogenicity and consistency of immune responses Source: Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS‐CoV‐2 vaccine (BBV152): a, double‐blind, randomised, controlled phase 3 trial; Ella, Reddy, Blackwelder, Potdar, et al.; medRxiv 2021.06.30.21259439; accessed July 7, 2021
15©2021 Ocugen. All Rights Reserved. Phase 3: Study Outline
16©2021 Ocugen. All Rights Reserved. Phase 2: Study Results • 6µg +Algel‐IMDG demonstrated high neutralizing Abs responses compared to 3µg + Algel‐IMDG group • Mean GMT (95% CI) higher than human convalescent serum (HCS) • 6µg +Algel‐IMDG (Covaxin™) selected for Phase 3 study
17©2021 Ocugen. All Rights Reserved. Phase 2: Study Results • High Seroconversion rates (>96%) in both MNT50 and PRNT50 measured up to day 56 • Induction of Th1 cell mediated immunity as measured by IFN‐ƴ, IL‐2, TNF‐α • No vaccine‐related severe or life‐ threatening adverse events reported to date Events Rate (%) CI Local 4.2% (1.8, 8.1) 95% Systemic 7.4% (4.1, 12.1) 95% Serious 0% Combined 10.3% (7.4, 13.8) 95% Safety
18©2021 Ocugen. All Rights Reserved. Additional Research Demonstrating Effect Against Multiple Variants B.1.617 (India ‐ Kappa) B.1.1.7 (United Kingdom ‐ Alpha) B.1.1.28 (Brazil P2 ‐ Zeta) • COVAXIN‐vaccinated sera effectively neutralized several SARS‐CoV‐2 variants in an in‐vitro plaque reduction neutralization assay • The study was conducted by Indian Council of Medical Research (ICMR)‐ National Institute of Virology • These studies suggest that COVAXIN vaccination may be effective against multiple SARS‐CoV‐2 variants.
19 Ocugen’s Modifier Gene Therapy Platform Breakthrough Technology Designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors
20©2021 Ocugen. All Rights Reserved. Novel approach that targets nuclear hormone genes (NHRs), which regulate multiple functions within the retina Smoother regulatory pathway due to ability to target multiple diseases with one product Ability to recoup development costs over multiple therapeutic indications Gene Augmentation: Transfer functional version of a non-functional gene into the target cells. Modifier Gene Therapy: Introduce a functional gene to modify the expression of many genes, gene-networks and regulate basic biological processes in retina Traditional approach that targets one individual gene mutation at a time Regulatory pathway focused on specific product for one disease Longer time to recoup development costs Cell with mutated/ nonfunctioning gene X Cell with mutated/nonfunctioning gene(s) other than modifier gene Cell with normal function GENE X GENE X GENE X GENE X GENE X GENE X Normal gene X GENE X GENE M Modifier gene M Cell Cell Cell Cell GENE M GENE X Cell Cell We can address a number of diseases using the same Modifier Gene product. Traditional Gene Therapy ONE Disease Traditional Approach vs. Ocugen’s Novel Platform Rhodopsin Mutation-Associated Retinal Disease OCU400 Broad Spectrum Therapy for RPCEP290 Mutation-Associated Retinal Disease PDE6B Mutation-Associated Retinal Disease NR2E3 Mutation-Associated Retinal Disease
21©2021 Ocugen. All Rights Reserved. Why Target Nuclear Hormone Receptor Genes (NHRs)? Modulators of retinal development & function Act as “master genes” in the retina Molecular reset of key transcription factors and associated gene networks – retinal homeostasis Gene modifier concept including impact on clinical phenotypes is well known in other disease areas, CF and SMA * Inflammation & Cell Survival Phototransduction Metabolism Photoreceptor Development Cone Cell Development NR2E3 NR1D1 RORA Key Mutations: RGR, RHO, PDE6 Key Mutations: PRP16, OTX Key Mutations: GNB3, RP78, GNAT Key Mutations: PEX7 Key Mutations: NR2E3, RP68 * References: https://pubmed.ncbi.nlm.nih.gov/28556246/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409218/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339951/ https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0183526
22©2021 Ocugen. All Rights Reserved. Efficacy results shown in 5 unique mouse models of RP Technology developed at Harvard Medical School, Dr. Neena Haider’s Lab Study demonstrates potency of modifier gene therapy to elicit broad‐spectrum therapeutic benefits in early and advanced stages of RP Results show evidence of vision rescue in Early & Advanced Stages of disease https://www.nature.com/articles/s41434‐020‐0134‐z Preclinical POC Data for Nr2e3 Published in Nature Gene Therapy Important milestone for development of therapy; demonstrated proof of principle Protection elicited in multiple animal models of degeneration caused by different mutations Potential to represent first broad‐spectrum therapy and to provide rescue even after disease onset Nature Gene Therapy Publication
23©2021 Ocugen. All Rights Reserved. Human Diseases: Control PDE6 associated RP Rhodopsin associated adRP Leber Congenital Amaurosis Enhanced S‐cone Syndrome • P0 single subretinal injection, evaluation 3‐4 months post injection • rd1 evaluated one‐month post injection ONL: Outer Nuclear Layer • P21 subretinal injection, evaluation 2–3 months post injection • Restored ONL photoreceptors morphology in rd7 • ONL cell layer change in rd7 model doesn’t progress until 4‐5 mos. of age Fundus images and ONL count show how single product recuses vision in multiple mutations https://www.nature.com/articles/s41434‐020‐0134‐z OCU400 – Rescue in Early & Advanced Stage of Disease Early Stage Rescue Advanced Stage Rescue
24©2021 Ocugen. All Rights Reserved. ERG response: P0 single subretinal injection, evaluation 3‐4 months post injection Human vision is enabled by three primary modes: • Photopic vision: Vision under well‐lit conditions, which provides for color perception and functions primarily due to cone cells in the eye • Mesopic vision: A combination of photopic vision and scotopic vision in low lighting, which functions due to a combination of rod and cone cells in the eye • Scotopic vision:Monochromatic vision in very low light, which functions primarily due to rod cells in the eye https://www.nature.com/articles/s41434‐020‐0134‐z OCU400 – Demonstrates Improved Vision Signals in Retina Electroretinogram (ERG) Response Reveals Rescue under Both Scotopic (dim‐lit) as well as Photopic (well‐lit) Conditions
25©2021 Ocugen. All Rights Reserved. https://www.nature.com/articles/s41434‐020‐0134‐z Study Results Confirm Overexpression of Nr2e3 by subretinal AAV8‐Nr2e3 Injection Is Not Detrimental to Retina – No Off‐Target Effects OCU400 – Demonstrated Safety in Mouse Model
26©2021 Ocugen. All Rights Reserved. Phase 2b/3Phase 1/2a NR2E3 RHO NR2E3 RHO CEP290 Potential Approval Proposed Broad RP Indication Phase 4 Commitments OCU400 NR2E3 Mutation-Enhanced S-cone Syndrome Rhodopsin Mutation-Associated Retinal Disease CEP290 Mutation-Leber Congenital Amaurosis Broad Spectrum Therapy for RP 2021 ‐ 2022 2023 ‐ 2025 2025/26 OCU400 – Clinical and Regulatory Strategy Planned Timeline Successfully completed manufacturing at commercial scale (200L) at CanSinoBio to support clinical studies Preclinical tox studies in‐progress On target to file IND in 2H21
27©2021 Ocugen. All Rights Reserved. Features OCU400 Traditional Gene Therapy Cell Therapy One product for many IRDs (including broad RP indication) Limited Technology established in the ocular disease space POC data in RP models with different genetic mutations Expected long‐term outcome Potentially longer benefit due to promotion of homeostasis Potentially limited due to loss of retinal cells over time Not established Target Patient Population Large Small (specific to mutation) Variable Developmental cost Low (economies of scale) High (No economies of scale) High OCU400 – Competitive Overview Potential Competitors pursuing treatment of RP with Traditional Gene Therapy Potential Competitors pursuing treatment of RP with Cell Therapy
28©2021 Ocugen. All Rights Reserved. Dry AMD Leads to irreversible blindness due to degeneration of the retina ~9‐10M patients in the U.S. Currently no approved treatment for Dry AMD Contributing Factors Aging Genetics Environmental Factors Normal Retina Dry AMD Oxidative Stress RORA Inflammation Lipid Peroxidation References: https://www.brightfocus.org/macular/article/age‐related‐macular‐facts‐figures https://www.uniprot.org/uniprot/P35398#function https://pubmed.ncbi.nlm.nih.gov/21998696/ https://pubmed.ncbi.nlm.nih.gov/19786043/ OCU410 (AAV‐RORA) – Dry Age‐Related Macular Degeneration We Believe OCU410 Has the Potential to Address this Disease through its Multi‐Factor Approach
29 OCU200: Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Wet Age‐Related Macular Degeneration (Wet AMD) Novel Biologic Offering Benefits Beyond Anti‐VEGF
30©2021 Ocugen. All Rights Reserved. DME ~0.7M patients in the US* DR ~7.7M patients in the US* Wet AMD ~1.1M patients in the US* OCU200 is a Transferrin‐Tumstatin Fusion Protein • Tumstatin: Multiple MOAs for treatment and prevention of macular degeneration and neovascularization • Transferrin: Targets the site of action and improves uptake (better target engagement) Integrin Targeting provides hope to these patients who are non‐responders to current therapies Distinct MOA through targeting Integrin pathways can potentially also help reduce number of injections for patients who do respond to Anti‐VEGF & corticosteroids therapies Significant global market potential ~50% of Patients DO NOT Respond to Anti‐VEGF/Corticosteroids Therapies OCU200 – Potential to Treat DME, DR & Wet AMD OCU200 Provides Hope to All patients with DME, DR or Wet AMD https://www.gene.com/stories/retinal‐diseases‐fact‐sheet https://www.brightfocus.org/macular/article/age‐related‐macular‐facts‐figures (*)
31©2021 Ocugen. All Rights Reserved. Data expressed as percentage of CNV lesions on Day 10 after treatment. Laser induction & treatment start on Day 0 Wet AMD In‐Vivo Laser‐Induced Mouse CNV Model * indicates p<0.05 when compared to PBS and/or tumstatin treatment † indicates p<0.05 when compared to Avas n; CNV lesions measured on day 14 after treatment Wet AMD In‐Vivo Laser‐Induced Rat CNV Model AvastinOCU200TumstatinPBS DME/DR Oxygen‐Induced Retinopathy (OIR) Mouse Model Effect of OCU200 intravitreal treatments on Neovascularization (NV). Data are presented as mean± SD. Filled circles represent data points from individual eyes * P < 0.05, ** P < 0.01 (n = 9‐10 eyes per group) • Inhibits new blood vessel formation • Anti‐inflammatory • Anti‐oxidative OCU200 –Transferrin‐Tumstatin Fusion Protein OCU200 Demonstrated Superior Efficacy Compared to Existing Anti‐VEGF Therapies -50 0 50 100 150 Neovascular area (normalized) N V (% o f c on tro l r et in a N V) * ** **
32©2021 Ocugen. All Rights Reserved. Features OCU200 Anti‐VEGF Anti‐Integrin Reduces VEGF level/Fluid Selectively works on active endothelial cells (Neovascular) Activates native anti‐angiogenic response Enhanced effective delivery through Transferrin Pro‐apoptotic and anti‐oxidative Dosing Frequency Expected once in 3 months 1‐3 months 1‐3 months (1) Approved (1) (1) (1) OCU200 – Distinct Mechanism of Action Potential Competitors pursuing treatment using Anti‐VEGF approach Potential Competitors pursuing treatment using Anti‐Integrin approach We believe OCU200 has the potential to become a disease modifying therapeutic for broader patient population
33©2021 Ocugen. All Rights Reserved. Key Inflection Points COVAXIN™ ‐ Vaccine candidate for the US and Canadian markets with potential for revenues this year Ophthalmology • Modifier Gene Therapy Platform has the potential for one product to treat many diseases • Novel biologic has the potential to treat anti‐VEGF /corticosteroids non‐responders (~50% of the patients) • Multiple near and mid‐term milestones with plan to initiate four Phase 1/2 trials over next 18 months
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID‐19 For more information, contact: [email protected]